Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Bone marrow transplants (BMT) are one form of treatment for disorders of the blood, including leukemia. However, because the procedure is often associated with potentially life-threatening reactions, it is usually reserved for patients with serious illnesses under the age of 60 years old. One serious reaction complicating bone marrow transplants is referred to as graft-versus-host disease (GVHD). GVHD is a potentially fatal incompatibility reaction. The reaction is caused by antigens found on the cells of the patient that are not present on the cells of the donor. The antigens are recognized by transplanted white blood cells (lymphocytes). These lymphocytes begin attacking the recipient s cells and tissues and may lead to death. In order to avoid GVHD, researchers have developed a technique using peripheral blood instead of bone marrow that allows transplantation of stem cells and removal of lymphocytes. Stem cells are the cells responsible for returning blood cell production to normal. Lymphocytes are the white blood cells that can cause GVHD. The technique requires two steps. In the first step blood cells are collected from donors who have received doses of a growth factor. The growth factor (granulocyte colony stimulating factor) is designed to increase the production of donor stem cells. In the second step white blood cell lymphocytes are removed from the collected blood, leaving only the stem cells. The main goal of this study is to develop and improve the method of processing cells that are collected after stimulation with growth factor (G-CSF), by removing the white blood cell lymphocytes which can cause graft-versus-host disease (GVHD) while keeping the stem cells necessary for healthy blood cell building. In addition, researchers are interested in studying whether giving G-CSF has an effect on lymphocyte function, which may influence the immune reactions occurring in bone marrow transplantation.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoba zdrowa w wieku od 18 do 60 lat.
- •Brak aktywnej lub nawracającej infekcji.
- •Dobre wyniki badań nerek i wątroby.
- •Prawidłowe wyniki badań krwi (morfologia, liczba białych krwinek, płytek krwi, hemoglobina).
- •Sprawny układ krążenia, bez problemów z sercem czy udarów w przeszłości.
- •Kobiety w wieku rozrodczym muszą mieć negatywny test ciążowy.
- •Brak karmienia piersią.
- •Możliwość oddania krwi (negatywne testy na choroby zakaźne, np. wirusowe zapalenie wątroby, HIV).
✗ Disqualifies
- •Aktywna infekcja bakteryjna, wirusowa, grzybicza lub pasożytnicza.
- •Ciąża lub karmienie piersią.
- •Choroby autoimmunologiczne wymagające leczenia lub osłabienia odporności.
- •Aktywny lub niedawny nowotwór (w ciągu ostatnich 5 lat).
- •Nowotwory z przeszłości (starsze niż 5 lat), jeśli były niskiego ryzyka i są w remisji.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 60 Years
- Last updated (source)
- June 30, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
National Institutes of Health Clinical Center
Bethesda, United States
Trial contact
Richard A Gustafson, R.N.
Andre Larochelle, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.